ConTIPI Medical Receives $40 Million in Funding From Two Investors

Capital IP Investment Partners and Ghost Tree Partners have secured $40 million of structured capital for ConTIPI Medical Ltd., a company providing non-surgical and disposable solutions for women with various pelvic floor disfunctions. ConTIPI will use the money to commercialize its new product, ProVate.
 
After the success of ConTIPI’s Impressa Device for stress urinary incontinence and its acquisition by Kimberly Clark, the firm’s next focus is the ProVate Device, intended to manage pelvic organ prolapse (POP) in women. Current available POP treatment options involve invasive surgery, with a failure rate of up to 30%, or the use of non-invasive pessaries, which require a physician’s assistance and are associated with several adverse events. ProVate allows women to take control of their own treatment with a non-surgical and disposable solution. The solutions come ready-to-use within a disposable applicator to be used vaginally by the user at her will, very similar to a menstrual tampon. The device has a 510(k) clearance from the U.S. Food and Drug Administration and the CE mark in Europe.
 
Simultaneous with the financing, ConTIPI has established a commercial partnership with Indegene, a life science commercialization company, which will provide several services across the commercialization process including sales, PRMA (pricing, reimbursement, and market access), medical affairs, medical communications, pharmacovigilance, regulatory, marketing, and commercial operations support. Indegene will help ConTIPI deploy highly effective and efficient curated sales and marketing strategies.
 
“We are very excited to secure the financing round for the ProVate device, with experienced investors such as Capital IP and Ghost Tree Partners, and at the same time also close our agreement with Indegene. Gathering of secured capital, devoted financial advisors from Bourne Partners, and talented marketing, will drive the project to the place it deserves to be, helping millions of women, globally,” ConTIPI CEO/Medical Director Dr. Elan Ziv said.

Bourne Partners served as the exclusive financial advisor to ConTIPI Medical Ltd.
 
Capital IP Managing Partner Aron Dantzig, and Ghost Tree Partners Managing Director David Byrne, stated, “Capital IP and Ghost Tree Partners are excited to have provided a financing solution for ConTIPI’s ProVate device. POP is a prevalent condition affecting millions of women globally. The introduction of the ProVate device signifies a turning point in addressing these challenges. It empowers women to regain crucial control over their medical treatment and conveniently manage it within the comfort and privacy of their own homes. Capital IP and Ghost Tree believe [this device] will have a positive impact on the lives of women.”
 
ConTIPI Medical, and its associate company ConTIPI Limited, both located at the Caesarea Industrial Park in Israel, provide non-surgical and disposable vaginal solutions for women with various pelvic floor disorders.

Capital IP Investment Partners is a minority co-founded specialty credit firm focused exclusively on investments in technology and technology-enabled businesses. Its collaborative approach to investing, combined with technology-industry expertise, allows Capital IP to assess the intrinsic value of growing technology businesses and to offer a range of financing solutions. The principals of CapIP have historically invested more than $1.3 billion in emerging companies. 
 
Headquartered in Irvine, Calif., Ghost Tree Partners is an alternative asset manager that provides private credit financing solutions to small and middle-market borrowers in the United States and developed Europe and Asia. Founded in 2021, the firm is led by Mark Fox, Scott Warner, Jeff Willardson and David Byrne, who combine for more than 85 years of investment experience with Goldman Sachs, Bain Capital Credit, Fidelity and PAAMCO Prisma (KKR affiliate). At Ghost Tree, their private credit financing solutions include corporate cash flow loans, specialty finance, asset backed lending and real estate bridge loans.